Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00079430
Other study ID # NCI-2009-00620
Secondary ID NCI-2009-00620GO
Status Completed
Phase Phase 1
First received
Last updated
Start date June 2004

Study information

Verified date July 2019
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of adjuvant intraperitoneal carboplatin when given together with paclitaxel and bevacizumab in treating patients who have undergone debulking surgery for stage II , stage III, or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin and paclitaxel in treating ovarian epithelial or primary peritoneal cancer, or fallopian tube cancer.


Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of intraperitoneal carboplatin when administered with paclitaxel during course 1, in patients with stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer who had initial debulking surgery.

II. Determine the feasibility of this regimen in these patients. III. Determine the feasibility of adding IV bevacizumab to this regimen in courses 2-6.

SECONDARY OBJECTIVES:

I. Determine the toxicity profile of this regimen in these patients. II. Determine the toxicity profile of paclitaxel and bevacizumab IV in combination with intraperitoneal carboplatin in these patients.

III. Determine the response rate (in patients with measurable disease who are in the expanded cohort) and progression-free survival of patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of intraperitoneal carboplatin.

Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 20-40 patients are treated at that dose level.

Patients are followed every 3 months for 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 113
Est. completion date
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

- Stage II-IV disease

- The following histologic epithelial cell types are eligible:

- Serous adenocarcinoma

- Mucinous adenocarcinoma

- Clear cell adenocarcinoma

- Transitional cell carcinoma

- Adenocarcinoma not otherwise specified

- Endometrioid adenocarcinoma

- Undifferentiated carcinoma

- Mixed epithelial carcinoma

- Malignant Brenner's tumor

- Optimal (= 1 cm residual disease) OR suboptimal residual disease after initial debulking surgery (performed within the past 12 weeks)

- Synchronous primary endometrial cancer OR prior history of endometrial cancer allowed provided all of the following are true:

- Stage IB disease or less

- Less than 3 mm invasion without vascular or lymphatic invasion

- No poorly differentiated subtypes, including the following:

- Papillary serous

- Clear cell

- Other FIGO grade 3 lesions

- No epithelial tumors of low malignant potential (borderline tumors)

- No CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, or brain metastases by history or evidence upon physical examination within the past 6 months

- Performance status - GOG 0-2

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- INR = 1.5

- PTT < 1.2 times upper limit of normal (ULN)

- No active bleeding or pathologic conditions carrying high risk of bleeding (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels)

- AST = 3 times upper limit of normal (ULN)

- Alkaline phosphatase = 3 times ULN

- Bilirubin = 1.5 times ULN

- No acute hepatitis

- Creatinine = 2.0 mg/dL

- Urine protein-creatinine ratio < 1.0 OR protein 1.0 g by 24 hour urine collection

- Cardiac conduction abnormalities (e.g., bundle branch block or heart block) allowed provided the patient's cardiac status has been stable for = 6 months before study entry

- No clinically significant cardiovascular disease, including any of the following:

- Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg

- Myocardial infarction or unstable angina within the past 6 months

- New York Heart Association class II-IV congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Peripheral vascular disease = CTCAE grade 2 (at least brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit)

- No history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within the past 6 months

- Not pregnant or nursing

- Fertile patients must use effective contraception during and for = 6 months after completion of bevacizumab therapy

- No neuropathy (sensory and motor) > grade 1

- No active infection requiring antibiotics

- No circumstances that would preclude study participation

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies

- No history of allergic reaction to polysorbate 80 (e.g., etoposide, vitamin E)

- No other invasive malignancies within the past 5 years except non-melanoma skin cancer or localized breast cancer

- No serious, non-healing wound, ulcer, or bone fracture

- No significant traumatic injury within 28 days prior to bevacizumab therapy

- No prior history of abdominal fistula or gastrointestinal perforation within the past 3-6 months

- Granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection allowed but require weekly wound examinations

- No clinical symptoms or signs of gastrointestinal obstruction requiring parenteral hydration and/or nutrition

- At least 28 days since intra-abdominal abscess and recovered

- At least 3 years since prior adjuvant chemotherapy for localized breast cancer

- Patients must remain free of recurrent or metastatic disease

- At least 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin

- Patient must remain free of recurrent or metastatic disease

- No prior radiotherapy to any portion of the abdominal cavity or pelvis

- No concurrent amifostine or other protective agents

- No concurrent major surgical procedure or open biopsy or within 28 days prior to bevacizumab therapy

- No core biopsy within 7 days prior to bevacizumab therapy

- No prior therapy for this malignancy

- No prior cancer treatment that contraindicates study therapy

- No prior anti-VEGF drug, including bevacizumab

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
adjuvant therapy

Drug:
paclitaxel
Given IV
carboplatin
Given intraperitoneally
Biological:
bevacizumab
Given IV

Locations

Country Name City State
Japan Kawasaki Medical School Okayama-Ken Kurashiki
Japan Saitama Medical University International Medical Center Saitama
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland
United States Cooper Hospital University Medical Center Camden New Jersey
United States University of Chicago Chicago Illinois
United States Riverside Methodist Hospital Columbus Ohio
United States M D Anderson Cancer Center Houston Texas
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of California Medical Center At Irvine-Orange Campus Orange California
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Gynecologic Oncology Group Philadelphia Pennsylvania
United States Women and Infants Hospital Providence Rhode Island
United States Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle Washington
United States Pacific Gynecology Specialists Seattle Washington
United States Seattle Cancer Care Alliance Seattle Washington
United States University of Washington Medical Center Seattle Washington
United States Cancer Care Associates-Midtown Tulsa Oklahoma
United States Tulsa Cancer Institute Tulsa Oklahoma
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
National Cancer Institute (NCI) Gynecologic Oncology Group

Countries where clinical trial is conducted

United States,  Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of intraperitoneal carboplatin with intravenous paclitaxel, determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) 3 weeks
Primary Incidence of adverse events in patients given intraperitoneal carboplatin with intravenous paclitaxel at the MTD, assessed by CTCAE v3.0 12 weeks
Primary Number of observed DLTs in patients given intraperitoneal carboplatin with intravenous paclitaxel and intravenous bevacizumab, graded using CTCAE v3.0 6 weeks
Secondary Incidence of adverse events in patients given intraperitoneal carboplatin with intravenous paclitaxel and intravenous bevacizumab, graded using CTCAE v3.0 12 weeks
Secondary Response rate (in patients with measurable disease who are in the expanded cohort) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Up to 1 year
Secondary Progression-free survival assessed by RECIST From study entry until disease progression, death or date of last contact, up to 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03393884 - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) Phase 1/Phase 2
Completed NCT04546373 - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting NCT05456685 - IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Completed NCT01442051 - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Completed NCT02928549 - Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
Active, not recruiting NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Phase 2
Not yet recruiting NCT04983550 - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC Phase 2
Completed NCT02480374 - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer Phase 1
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Completed NCT03480750 - Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Phase 1/Phase 2
Completed NCT01610206 - A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Phase 2
Completed NCT01219777 - Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian Phase 1
Completed NCT01031381 - Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Phase 2
Completed NCT00959582 - Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) Phase 1
Suspended NCT00753480 - A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 1
Completed NCT00801320 - Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer N/A
Completed NCT00768144 - Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma Phase 2
Completed NCT00702299 - Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer Phase 1
Recruiting NCT02349958 - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Phase 2
Completed NCT00390234 - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Phase 2